A nationwide Swedish study of over 624,000 births suggests HPV vaccination may offer benefits beyond cancer prevention. Women vaccinated before age 17 showed 10% lower odds of preterm birth and 11% lower odds of spontaneous preterm birth. Preterm birth is a major contributor to neonatal mortality and later health sequelae.
Emerging evidence indicates HPV infection may contribute to preterm birth and other adverse pregnancy outcomes, raising the possibility of a preventable risk factor. Surgical excision of HPV-related precancerous and early cancerous cervical lesions has been associated with an increased risk of adverse pregnancy outcomes. HPV vaccination could therefore offer reproductive health benefits beyond its established role in preventing cervical precancer and cancer.
The study, utilizing 2006-2023 registry data, found vaccinated women were younger at childbirth and more likely to have Swedish-born mothers. Among unvaccinated women, 3.7% had a high-grade cervical lesion diagnosed before childbirth, compared to 0.6% in the vaccinated population. Adjusted analyses revealed lower odds of all adverse pregnancy outcomes, particularly preterm birth and spontaneous preterm birth, with 5% and 15% reductions, respectively. Significant associations were also observed for pPROM and severe SGA.
Vaccination before age 17 showed stronger protective associations, with 10% and 11% lower odds of preterm birth and spontaneous preterm birth. These findings are consistent with earlier Finnish studies, though those were limited by small sample sizes. The study adjusted for smoking, age at childbirth, body mass index, and assisted reproduction. The lowest estimates, ranging from 451 to 573, were observed for severe SGA, preterm birth, PROM, sPTB, and SGA. Despite limitations including potential residual confounding and the inability to capture certain events, the study reinforces earlier evidence and suggests HPV vaccination may offer additional reproductive benefits.